ArriVent BioPharma Inc. (Nasdaq: AVBP), a clinical-stage biopharmaceutical company, has released its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $95.8 million for the six months ended June 30, 2025, compared to a net loss of $39.3 million for the same period in 2024. The increase in net loss was primarily attributed to a one-time upfront payment of $40 million made to Lepu Biopharma and increased expenses related to clinical activities. Research and development expenses rose significantly to $89.0 million for the first half of 2025 from $38.8 million in the previous year. General and administrative expenses also increased to $11.4 million from $7.6 million year-over-year. As of June 30, 2025, ArriVent held cash and investments totaling $254.5 million. This figure does not account for the $81.1 million raised from a public offering in July 2025. Combined, these funds are expected to support the company's operations until mid-2027. Significant recent developments include positive interim Phase 1b results for firmonertinib in EGFR PACC mutant NSCLC and the dosing of the first patient in the Phase 1 Study for ARR-217 (MRG007), targeting CDH17 in gastrointestinal tumors. The global pivotal Phase 3 ALPACCA study is anticipated to enroll its first patient in the second half of 2025, and top-line data from the FURVENT Phase 3 study is expected in early 2026.